Home Alzheimer’s Disease Trastuzumab Deruxtecan Shows Antitumor Activity for Patients with HER2-Overexpressing NSCLC

Trastuzumab Deruxtecan Shows Antitumor Activity for Patients with HER2-Overexpressing NSCLC

Trastuzumab deruxtecan (Enhertu) treatment demonstrated strong antitumor activity for patients with HER2-overexpressing non–small cell lung cancer (NSCLC), regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial (NCT03505710) presented at the 2020 World Conference on Lung Cancer (WCLC) Singapore.1 

“The encouraging early efficacies support the continued exploration of [trastuzumab deruxtecan] in patients with HER2-overexpressing non–small cell lung cancer,” said Kazuhiko Nakagawa, MD, PhD, in a presentation during the International Association for the Study of Lung Cancer WCLC.

Trastuzumab deruxtecan is an antibody–drug conjugate (ADC) composed of an anti-HER2 antibody, a tetrapeptide-based linker, and a topoisomerase I inhibitor payload. The ADC earlier demonstrated promising activity in patients with…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments